Tianchen Biotechnology

Based in Tianjin, China, Tianchen (Tianjin) Biotechnology Co., Ltd. is a privately held company established in 2018 that specializes in the research, development, production, and sale of ophthalmic medical devices. The firm directs its efforts toward creating high-tech solutions for unmet clinical needs within the eye care sector, manufacturing both active medical devices and passive consumable products. Its client base includes both individual patients, for whom it provides portable treatment and care equipment, and medical institutions, which are offered comprehensive diagnostic and therapeutic solutions.

The company's product lines are segmented into categories for glaucoma and dry eye treatment. A notable achievement for the company was securing the Class III Medical Device Registration Certificate for its Ophthalmic Intense Pulsed Light (IPL) Therapeutic Device in late 2024. This was followed by the pioneering implantation of its Minimally Invasive Glaucoma Drainage System at Beijing Tongren Hospital. The business model appears to focus on the direct sale of these specialized medical devices and consumables to healthcare providers and patients.

Financially, Tianchen Biotechnology is venture-backed and has completed multiple rounds of funding. In March 2024, the company raised $13.9 million in a Series A1 round, with CMB International Capital participating as an investor. The company's team includes talent from prominent institutions such as Tsinghua University, Beihang University, and Tianjin University, bringing together expertise in materials science, optics, and clinical ophthalmology.

Keywords: ophthalmic medical devices, ophthalmology, glaucoma treatment, dry eye therapy, medical consumables, diagnostic solutions, therapeutic devices, eye care technology, Intense Pulsed Light therapy, Minimally Invasive Glaucoma Drainage System, medical device manufacturing, clinical ophthalmology, venture capital-backed, Tianjin, China, eye health, medical equipment